CellCarta: Adds Tempus to CDX commercialization lab network as second commercial lab partner

CellCarta, a global contract research organization (CRO) laboratory serving the biopharmaceutical industry, has added Tempus as its second commercial laboratory partner in its Lab Network strategy for companion diagnostic (CDx) commercialization. This partnership follows CellCarta’s earlier collaboration with Sonic Healthcare USA, Inc. in May 2026, marking bridge the gap between CDx development and large-scale commercial deployment.

Under the model, CellCarta develops CDx assays, generates the necessary analytical and clinical evidence, and supports regulatory approvals through the U.S. FDA and European IVDR pathways. Commercial partners like Tempus then facilitate the deployment of these diagnostics by interfacing directly with healthcare providers and patients, enabling broader access to precision medicine solutions.

Tempus, known for its comprehensive precision medicine laboratory capabilities in oncology, operates FDA-authorized assays and serves a network of over 7,500 oncologists. The company offers a multi-omics platform including next-generation sequencing (NGS), proteomics, and spatial transcriptomics, supported by advanced data analytics and project management. Its inclusion in CellCarta’s network is expected to enhance the scalability and reach of CDx solutions in oncology and other therapeutic areas.

CellCarta’s Lab Network strategy aims to provide biopharma sponsors with a centralized, high-quality CDx development and testing model while ensuring a scalable path to commercialization. The addition of Tempus reflects growing industry interest in this approach and CellCarta’s intent to expand its global network over time.